Ligand Pharmaceuticals | LGND - Debt


Ligand Pharmaceuticals reported $5.74M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Amgen USD 54.59B 1.62B Sep/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
Baxter International USD 9.73B 584M Jun/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Gilead Sciences USD 24.95B 6M Jun/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Insmed USD 564.56M 464K Sep/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Ligand Pharmaceuticals USD 5.74M 5.72M Jun/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Pacira USD 376.72M 203.77M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Veracyte USD 50.65M 145K Jun/2025